14/05/2025
I have submitted my response to the NICE draft consultation regarding fezolinetant, a much-needed non-hormonal treatment for menopause symptoms.
I am extremely disappointed by NICE's decision to reject its approval for NHS use. As a menopause specialist caring for women with a history of breast cancer, when HRT is often not recommended — I see first-hand how limited their treatment options are. Most alternatives are unlicensed and associated with significant side effects.
Fezolinetant offers a non-hormonal, evidence-based option. Its rejection overlooks the profound impact of untreated vasomotor symptoms, which many of my patients find more debilitating than their cancer treatment itself.
Comparisons with SSRIs are not appropriate; these are often prescribed only because no better options exist, reflecting the wider and longstanding underinvestment in women's health research.
We must do better. Continuing to deny access to this medication leaves too many women without meaningful support. The human and economic consequences of unmanaged menopausal symptoms in this important group must not be underestimated.
aihetunniste aihetunniste aihetunniste aihetunniste aihetunniste
